XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 43.73

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-18 )

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 10.12 % 0.00 %

N/A

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.72% 40% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.72% 40% F 54% F
Trailing 12 Months  
Capital Gain 5.22% 67% D+ 48% F
Dividend Return 1.63% 100% F 27% F
Total Return 6.86% 71% C- 40% F
Trailing 5 Years  
Capital Gain -7.49% 24% F 42% F
Dividend Return 5.43% 68% D+ 15% F
Total Return -2.05% 24% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain -1.68% 19% F 25% F
Dividend Return -0.93% 19% F 17% F
Total Return 0.74% 68% D+ 19% F
Risk Return Profile  
Volatility (Standard Deviation) 15.93% 67% D+ 64% D
Risk Adjusted Return -5.85% 14% F 17% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.